Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella, Inc.'s Antibiotic, SQ109, for Tuberculosis

ROCKVILLE, Md.--(BUSINESS WIRE)--Sequella, a clinical-stage pharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, licensed the late-stage development and commercialization of its lead antibiotic, SQ109, to a portfolio company of Maxwell Biotech Venture Fund Infectex in 2011. Infectex has recently received notification from the Russian Ministry of Health for approval to begin the pivotal clinical trial associated with a drug registration submission, and can now proceed with the clinical development of SQ109 for treatment of tuberculosis (TB) in the Russian Federation.